Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up StudyI‐Cheng Lee, Yi‐Hsiang Huang, Sien‐Sing Yang et al.|The Journal of Infectious Diseases|2018Cited by 28
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelinesWei Teng, Jaw‐Ching Wu, Hwai‐I Yang et al.|Hepatology International|2021Cited by 27
Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis CShih-Jer Hsu, Wan‐Long Chuang, Ming‐Lung Yu et al.|Journal of the Formosan Medical Association|2020Cited by 22
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutionsMing‐Lung Yu, Ding‐Shinn Chen, Chao‐Hung Hung et al.|Journal of the Formosan Medical Association|2018Cited by 11
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected PatientsChi-Chieh Yang, Ming‐Lung Yu, Wei-Lun Tsai et al.|PLoS ONE|2015Cited by 9